Stefan Moese, NovaGo Therapeutics

CEO

“Our collaboration with FGK has been smooth and efficient so far. Their flexibility and reliability have made a significant contribution to the progress of our Phase Ib study in acute spinal cord injury. We particularly value the open and clear communication between our teams, which makes working together both effective and pleasant.”